大博医疗(002901) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥550,336,243.99, representing a 28.80% increase compared to ¥427,279,900.69 in the same period last year[5] - Net profit attributable to shareholders was ¥103,101,566.47, a 67.04% increase from ¥61,728,900.60 year-on-year[5] - The net profit excluding non-recurring gains and losses was ¥97,121,145.10, reflecting a 96.76% increase from ¥49,360,290.32 in the previous year[5] - Basic and diluted earnings per share increased to ¥0.25, up 66.67% from ¥0.15 in the same period last year[5] - Total operating revenue for the current period reached ¥550,336,243.99, a 28.8% increase from ¥427,279,900.69 in the previous period[20] - Net profit for the current period was ¥112,540,587.80, representing a 67.5% increase compared to ¥67,189,591.05 in the previous period[22] - The net profit attributable to the parent company was ¥103,101,566.47, an increase of 67.0% from ¥61,721,780.54 in the previous period[22] - Basic and diluted earnings per share were both ¥0.25, up from ¥0.15 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,466,146,307.28, a 1.07% increase from ¥4,418,929,603.41 at the end of the previous year[5] - The total liabilities decreased to ¥1,159,421,730.86 from ¥1,237,317,657.89, reflecting a reduction of approximately 6.3%[18] - Total equity increased to ¥3,306,724,576.42 from ¥3,181,611,945.52, marking a growth of about 3.9%[18] - Cash and cash equivalents decreased to CNY 992,975,831.66 from CNY 1,075,945,032.18, reflecting a decline of approximately 7.7%[17] - The company's inventory increased slightly to CNY 1,279,032,418.71 from CNY 1,272,779,370.13, indicating a growth of about 0.5%[17] - Accounts receivable rose to CNY 274,960,293.37 from CNY 235,579,112.44, representing an increase of approximately 16.7%[17] - The company’s total current liabilities were not specified, but accounts payable decreased to CNY 230,735,204.91 from CNY 253,321,886.53, a decline of about 8.9%[17] Cash Flow - Cash flow from operating activities decreased by 50.78% to ¥25,921,050.26 from ¥52,671,456.22 in the same period last year[5] - Cash generated from operating activities was ¥578,784,826.37, compared to ¥465,773,219.88 in the previous period, indicating a significant increase[23] - Operating cash inflow totaled CNY 591,963,842.26, an increase from CNY 491,372,096.12 in the previous period, reflecting a growth of approximately 20.4%[24] - Operating cash outflow amounted to CNY 566,042,792.00, compared to CNY 438,712,506.67 previously, indicating an increase of about 29.0%[24] - Net cash flow from operating activities was CNY 25,921,050.26, down from CNY 52,659,589.45, representing a decline of approximately 50.8%[24] - Cash inflow from investment activities was CNY 299,293,783.06, a decrease from CNY 610,194,154.70, reflecting a decline of about 51.0%[24] - Cash outflow from investment activities reached CNY 464,037,838.03, down from CNY 763,145,715.43, indicating a decrease of approximately 39.2%[24] - Net cash flow from investment activities was -CNY 164,744,054.97, compared to -CNY 152,951,560.73 previously, showing a slight increase in negative cash flow[24] - Cash inflow from financing activities totaled CNY 4,871,776.00, significantly lower than CNY 43,105,137.86, a decrease of about 88.7%[25] - Cash outflow from financing activities was CNY 6,276,269.71, down from CNY 95,931,087.04, indicating a reduction of approximately 93.5%[25] - The net increase in cash and cash equivalents was -CNY 136,692,671.36, compared to -CNY 147,464,735.32 previously, showing a slight improvement in cash flow[25] - The ending balance of cash and cash equivalents was CNY 107,823,943.09, down from CNY 129,729,669.30, reflecting a decrease of approximately 16.9%[25] Shareholder Information - The company has a significant shareholder structure, with the largest shareholder holding 23.46% of the shares[13] - The top ten shareholders hold a total of 97,124,098 shares, which are unrestricted[14] - The company has a repurchase account holding 7,409,900 shares, representing 1.79% of total shares[14] - There were no changes in the participation of major shareholders in margin trading or securities lending during the reporting period[14] Strategic Initiatives - The company is exploring new strategies for market expansion and product development, although specific details were not disclosed in the call[15] Research and Development - Research and development expenses rose to ¥76,398,441.76, up from ¥59,950,671.27, indicating a focus on innovation[21] Financial Expenses - The company reported a decrease in financial expenses, with a net financial cost of -¥17,435,025.93 compared to -¥769,445.35 in the previous period[21]